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ABSTRACT
Nitrc oxide is a ubiquitous signaling molecule with both physiological and
pathological functions in biological systems. Formed by the enzmatic conversion of
arginine to citrlline, NO, has known roles in circulatory, imune and nerous tissues.
In the nerous system nitrc oxide has been implicated in long-ter potentiation
neurotranmitter release, chanel function, neuronal protection and neuronal
degeneration. Much of our work has focused on yet another role for nitrc oxide in cells
namely, neuronal differentiation.
Dung development, neuronal differentiation is closely coupled with cessation of
proliferation. We use nere growth factor (NGF)-induced differentiation ofPC12
pheochromocytoma cells as a model and fid a novel signal tranduction pathway that
blocks cell proliferation. Treatment ofPC12 cells with NGF leads to induction of nitric
oxide synthase (NOS). The resulting nitrc oxide (NO) acs as a second messenger
activating the p21(WAFl) promoter and inducing expression ofp21(WAFl) cyclin-
dependent kiase inibitor. NO acivates the p21 (W AFl) promoter by p53-dependent and
p53-independent mechanisms. Blocking production of NO with an inhibitor of NOS
reduces accumulation ofp53 , activation ofthe p21(WAFl) promoter, expression of
neuronal marker, and neurte extenion. To detere whether p2 1 (WAF 1) is required
for neurite extension, we prepared a PC 12 line with an inducible p21 (W AFl) expression
vector. Blocking NOS with an inhibitor decreases neurite extension, but induction of
p21 (W AFl) with isopropyl- thio-beta- D-galactopyranoside restored this response.
Levels of p21 (W AFl) induced by isopropyl- thio-beta- D-galactopyranoside were
similar to those induced by NGF. Therefore, we have identified a signal transduction
pathway that is activated by NGF; proceeds through NOS , p53 and p21 (W AFl) to block
cell proliferation; and is required for neuronal differentiation by PC12 cells.
In fuher studies of this pathway, we have examed the role of MA kinase
pathways in neuronal nitric oxide synthase (nNOS) induction during the differentiation of
PC12 cells. In NGF-treated PC12 cells, we find that nNOS is induced at RNA and
protein levels, resulting in increased NOS activity. We note that neither nNOS mRA
nNOS protein nor NOS activity is induced by NGF treatment in cells that have been
infected with a dominant negative Ra adenovis. We have also used drgs that block
MA kinase pathways and assessed their ability to inibit nNOS induction. Even though
U0126 and PD98059 are both MEK inhibitors, we fmd that U0126, but not PD98059
blocks nNOS induction and NOS activity in NGF-treated PC12 cells. Also, the p38
kinase inibitor, SB 203580, does not block nNOS induction in our clone ofPC12 cells.
Since the JNK pathway is not activated in NGF-treated PC12 cells, we deterne that the
Ras-ERK pathway and not the p38 or JN pathway is required for nNOS induction in
NGF-treated PC12 cells. We find that U0126 is much more effective than PD98059 in
blocking the Ra- ERK pathway, thereby explaining the discrepancy in nNOS inhibition.
We conclude that the Ras- ERK pathway is required for nNOS induction.
The activation of soluble guanylate cyclase and the production of cyclic GMP is
one of the best characterized modes of NO action. Havig shown that inhibition of NOS
blocks PC12 cell differentiation we tested whether nitric oxide acts through soluble
guanylate cyclase to lead to cell cycle arest and neuronal differentiation. Unlike NOS
inibition, the inibition of soluble guanylate cy1case does not block the induction of
neuronal markers. Moreover, treatent ofNGF-treated, NOS-inhibited PC12 cells with a
soluble analog of cyclic GMP was unable to restore differentiation of those cells. Hence
cGMP is not a component of this pathway and we had to consider other mechanisms of
NO acion.
It has become increasingly evident that another manner by which NO may exert
its effects is by S-nitrosylation of cysteine residues. We tested, 
in vitro whether nitric
oxide may control p53 by S-nitrosylation and inactivation of the p53 negative regulator
Hdm. Treatment of Hdm with a nitric oxide donor inhibits Hdm2-p53 binding, the
first step in Hdm regulation of p53. The presence of cysteine or DTT blocks this
inhibition of binding. Moreover, nitric oxide inibition ofHdm-p53 binding was found
to be reversible. Sulfhydrl-sensitivity and reversibility are consistent with nitrosylation.
Finally, we have identified a crtical cysteine residue that 
nitrc oxide modifies in order 
disrupt Hdm-p53 binding. Mutation of this residue from a cysteine to an alanine does
not interfere with binding but rather eliminates the sensitivity ofHdm to nitric oxide
inactivation.
, .,
VII
TABLE OF CONTENTS
Page
TITLE PAGE
APPROVAL PAGE
ACKNOWLEDGMENTS
ABSTRACT IV-VI
TABLE OF CONTENTS VII
LIST OF TABLES AN FIGURS VI11-1X
CHATER I. INRODUCTION
CONTRIUTIONS PAGE
CHATER n. A NOVEL, NERVE GROWTH
FACTOR-ACTIVATED PATHWAY INOLVIG
NITRIC OXIE, p53, andp21WAFl REGULATES
NEURONAL DIFFERENTIATION OF PC12 CELLS.
16-
CHATER m. THE RAS-MA KIASE PATHWAY
IS REQUID FOR THE INUCTION OF NEURONAL
NITRIC OXIE SYNTHASE IN DIFRENTIATING
PC12 CELLS.
40-
CHATER IV. NITRIC OXIE DOES NOT ACT
THROUGH GUANLATE CYCLASE DURG
THE DIFRENTIATION OF PC12 CELLS.
64-
CHATER V. NIRIC OXIE INITS HDM2-p53
BINING THROUGH S-NITROSYLATION OF HDM2.
71-
CHATER VI. ADDITIONAL DISCUSSION 89-
REFERENCES. 92- 107
;;u
VI11
LIST OF FIGURS AN TABLES
Page
Table 1-1. Major Reactions of NO
Table 1-2. S-nitrosylated proteins
Figure 1-1. Biosynthesis of nitrc oxide
Figure 1-2. Strcture ofL-NAME
Figure 1-3. Strcture ofDETA NONOate
Figue 1-4. The p53-Mdm autoregulatory loop
Figue 1-5. Strcture of MA kinase pathway inhibitors
Figue 2-1. NGF-induced expression ofMAIB 
dependent on NO.
Figue 2-2. NGF-induced expression ofnAChR is
dependent on NO.
Figue 2-3. NGF and NO enance expression ofp53
and p21 W AFI.
Figue 2-4. Activation of p21 W AFI promoter by NGF
and NO.
29-
Figure 2-5. Differentiated PC12 cells express NOS
andp21WAFl.
Figue 2-6. Role ofp21WAFl in NGF-induced differentiation.
Figure 2-7. Expression of p21 W AFI by NGF and IPTG.
Figure 3-1. nNOS is induced at the RNA, protein and activity
levels.
48-
Figure 3-2. Ras is required for the induction of NOS. 50-
Figure 3-3. Effect ofMEK inhibitors on nNOS induction. 53-
i 1
. i
: 1
Figure 3-4. Effect ofMEK inhibitors on neurte extension. 56-
Figue 3-5. Effect ofMEK inhibitors on ERK phosphorylation.
Figure 4-1. LY83583 does not inhibit NGF-induction of
f3-tubulin m.
Figue 4-2. 8 Bromo-cyclic GMP canot rescue L-NAM
inibited differentiation.
Figue 5-1. DETNNO inibits Hdm-p53 binding.
Figue 5-2. DTT blocks DETNNO inhibition ofHdm-p53
binding.
Figure 5-3. Cysteine blocks NO inhibition ofHdm-p53 binding.
Figue 5-4. DETNNO inhibition ofHdm-p53 binding is
reversible.
Figure 5-5. The N-ternus ofHdm contais three cysteines
(C2, C77 and CI27).
Figue 5-6. Wild tye and mutant Hdm bind to p53 simlarly.
Figure 5-7. Mutant Hdmlacks responsiveness to DETNNO.
Figure 5-8 A. Cys77 is in close proximty to other residues
that bind p53.
Figure 5-8 B. Cys77 is located in a hydrophobic pocket.
Figue 6-1. A signal transduction pathway important for the control
of neuronal differentiation.
CHATER I
INTRODUCTION
Chemistry of nitrc oxide
Nitric oxide is a unique and ubiquitous signaling molecule. While the chemistry
of NO is complex and has been reviewed elsewhere, several asects ofthis chemistr
bear mentioning here. NO is a free radical that is highly diffuible because of its low
molecular weight and high solubility. Limits on this diffusion exist, however, due to its
many chemical interactions. The three most imortant of these are interactions with
superoxide anion, transition metals, and thiol groups in proteins (1-5) (Table 1).
Nitric oxide reacts with the superoxide anion, O , to form the potent oxidizer
peroxyitrte (Table 1). Peroxynitrte is a chemically complex molecule that can react
with sulthydrls and zinc thiolate moieties. Peroxyitrite can also nitrate and
hydroxylate aromatic amo acid residues. Finally, it can oxidize lipids , DNA and
protein and is thought to be the key mediator of NO-induced cytotoxicity and
neurodegeneration (1-3).
Nitric oxide can reac with transition metals like the iron in heme groups (Table
1). Probably the best characteried NO modification of a heme-containing protein is
soluble guanylate cyclase. Nitric oxide binds the heme moiety of soluble guanylate
cyclase producing a conformtional change that activates the ene, resulting in the
increased production of cyclic GMP (1). The NO-heme modification is reversible, thus
serng as a mean of regulating the enzme. Targets of cGMP include cGMP-dependent
protein kinase, cGMP-gated ion channels and cyclic nucleotide phosphodiesterases (1 4).
Additional heme-containing proteins that are targets for NO include hemoglobin, and
cyclooxygenase (3 6).
TABLE 1
MAJOR REACTIONS OF NO
1. Reaction of NO with superoxide (0
NO + 02 -- OONO-
2. Reaction of NO with tranition metals (M)
NO + M -- NO-
3. Reaction of NO with thiols (RSH)
NO+ + RSH -- RS-NO + W
Recently, it has become apparent that nitrosylation of cysteine residues by nitric
oxide is a major regulatory reaction (Table 1). Whle nitrosylated cysteine residues are
labile and diffcult to detect, several examples are now known. S-nitrosoalbumin, and S-
nitrosoglutathione (GSNO) and S-nitrosocysteine all can serve as intracellular pools of
NO (5). Meanwhile nitrosylated hemoglobin serves as a sensor for blood flow depending
on the availability of oxygen (7). In addition there are now examles of pro teases
transcription factors , and receptors that are S-nitrosylated (Table 2).
The specificity of S-nitrosylation can be achieved by subcellular localization of
nitrc oxide synthases, enzyes responsible for the production of NO. Similar to NO
modification of heme-containing proteins, S-nitrosylation is reversible. This reversibility
distinguishes nitrosylation from some other tyes of oxidation which are ireversible and
can be toxic (2). NO itself is regulated by oxidation/reduction reactions. NO' , NO- and
+ are all of potential biological significance but in the case of S-nitrosylation it is
nitrosium ion (NO ) that reacts effciently with sulfhydrls (4 9).
A family ofthree nitric oxide synthase protein; neuronal NOS (nNOS),
endothelial NOS (eNOS) and inducible NOS (iNOS) (Figure 1-1) synthesize nitric oxide
from arginine (Figure 1-1). Both eNOS and nNOS are Ca2+ -dependent while iNOS is
+ -
independent. nNOS and iNOS exist in both soluble and membrane-bound form
while eNOS is exclusively membrane-bound (3). All three NOS genes have been deleted
in mice. nNOS null mice have changes in their resistance to stroke and in their behavior
but no changes were observed in hippocamal long term potentiation (10). iNOS nun
mice have increased susceptibility to bacteral and viral infections. These mice also
exhibit an increased vulnerability to tuor development (11 12). Finally, eNOS null
Table 2
Nitrosylated Proteins
Protein Reference
(13)
Src kinase (14)
GAPDH (15 16)
Transcription Factors
Acel (17)
Jun (18)
Receptors
EGF- (19)
yanodie receptor (20 21)
NMA receptor (22)
Glucocorticoid receptor (23)
NO pools
Hemoglobin (7)
Albumin (8)
Proteases
Caspase- (24-26)
Papain (27)
mv -protease (28)
....
NH2 NH2
nitric oxide synthse
(NOS)
NADPH
NH3 coo- NH3 coo-
Figure 1-1. Biosynthesis of nitrc oxide by nitrc oxide synthase
mice are deficient for acetlcholine-induced vasodilation and have elevated blood
pressure. These mice also demonstrate an increased susceptibility to stroke (3).
The study of nitric oxide has been enhanced considerably by the existence of
drgs that can either release nitric oxide (NO donors) or inibit nitrc oxide production
(NOS inhibitors). While there are numerous NO donors and NOS inhibitors and the
chemistr of these drgs has been studied thoroughly, we wil highlight just one donor
and one NOS inibitor that we emloyed extenively. L-NAM (N"-nitro-L-argiine) is
one of the more commonly used inibitors (Figue 1-2). This arginine analog is 
competitive inibitor of NOS and does not show NOS isoform specificity. One
advantage of this drg is the ability to use the inacive enantiomer, D-NAM, as a
negative control. DET A NONOate belongs to the class of NO NO ate nitrc oxide donors
(Fig 1-3). NONOates are adducts of NO with nuc1eophiles in which a nitrc oxide dimer
is formlly bound to the nucleophilic residue via a nitrogen atom NONOates release NO
spontaneously, and the rate of release is unaffected by biological reactants (9).
DETNNONOate is also ver useful in cell-based assays because of its long half-life (9).
Neuronal differentiation and cessation of proliferation
Neuronal differentiation refers to the physiological, biochemical and
morphological changes that cells undergo in order to become mature neurons. The
neurotrophins are a famly of proteis that sere as differentiation factors. One of these
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Figure 1-2. NOS inhibitor l' Nitro- arginine methyl ester
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Figure 1-3. Strcte ofDETA NONOate
neurotrophins, NGF, is a surval and differentiation factor for sympathetic and some
tyes of sensory neurons (29 30). The discover of the NGF receptor TrkA, which
belongs to a family of tranmembrane receptors with tyosine kinase activity has resulted
in an improved understanding ofNGF-mediated signal transduction (31-34). PC12 cells
a transformed rat pheochromocytoma cell line, have been an important tool in the NGF
field. Upon stiulation with NGF, these cells extend neurtes and differentiate into
symathetic-like neurons (35).
Cessation of proliferation is a key aspect of neuronal differentiation. Two key
proteins involved in cessation of proliferation durg neuronal differentiation are p53 and
p21 W AFI. p21 W AFI is a cyclin-dependent-kiase inhibitor that binds cdc2, cdk and
cdk4 (36 37) and is important in blocking the cell cycle at the Gl-S transition (38 39).
Mice lacking p21 W AFI undergo norml development suggesting there is significant
redundacy in its function. However, these mice also demonstrate some deficiencies in
G 1 checkpoint control (40). p21 W AFI is required for surval of differentiating
neuroblastoma cells and differentiated PC 12 cells express elevated levels of p21 W AFI
(41 42).
The p53 tumor suppressor protein is involved in growth arest and apoptosis
(reviewed in (43-45). One way that p53 fuctions to block cell cycle progression is by
inducing transcription of p21 W AFI (36,46). Accordingly, p53 blocks the cell cycle, like
p21WAFl , at the G S tranition (38 46). Work with p53 knockouts has revealed a
role for p53 in neuronal development. p53 knockout mice have a large number of birh
.II
"':\
defects such as failure of neural tube closure (47). As with p21WAFl , p53 is induced in
NGF-treated PC12 cells (48).
A key player in the regulation of p53 is the Mdm protein. The mdm gene was
fIrst detected in a screen for oncogenes present on a mouse double minute chromosome
(49). Mdm can regulate p53 in two ways. Mdm2 binds p53 and can block its ability to
activate transcription (50). Mdm also regulates p53 levels by promoting its degradation
(51 52). Conversely, p53 stimulates the transcription ofthe mdm gene thus formng a
negative feedback loop for the tight control ofp53 levels (53 54) (Figue 1-4).
MA kiase pathways durig neuronal dierentiation
Mitogen-activated protein (MA) kinases, found in all eukarotes, are common
paricipants in signal transduction pathways from the membrane to the nucleus. The core
unit of MA kinase pathways is a three-member protein kinase cascade. MAKs are
phosphorylated and activated by MAK kinases (MK) which are in tur activated and
phosphorylated by MK kinases (MK) (55 56). In mammals, the MA kinase
pathways can be organized into three main groups (57). The Ras-Raf-MEK-ERK
pathway is important for mitogenic, differentiation and surval responses (58-60).
ERKI and ERK are the best studied MA kinases of this pathway family. The other
two MA kinase pathways are, in general, more involved in stress and apoptotic
responses and are refered to as the JN pathway and the p38 kinase pathway. JN, of
which there are three, were isolated and characterized in par by their ability to
Prein-proein interaction
(t 
-- 
indin
Transcription Trasl ion omai
mdm2 gene
Other p5 target gees
Mdm2 protein
Figure 1-4. The p53-Mdm autoregulatory loop (45).
phosphorylate the trancription factor c-Jun and are strongly activated by stress-inducing
stimuli (61-63). The third MA kinase, p38 , is a homolog ofthe yeast HOG1. 
mammalian cells , the p38 kiase pathway is induced by lipopolysaccharde and high
osmolarity. Curently, four isoform ofp38 MA kinase are known (59 62). Hence,
the MA kinase pathways act as conduits , conveying informtion from the cell surface to
the cytoplasm and nucleus.
In PC12 cells, the Ras-ERK pathway plays a critical role in transmitting signals from
NGF. Upon binding ofNGF to its receptor TrkA, adptor molecules Shc, Grb2 , and Sos
recrit and actvate the small G protein Ras (29). The acvation ofRas initiates a kinase
cascade that proceeds from Raf to MEK 1/2 to ERK 1/2. In PC 12 cells, NGF elicits a
sustained activation ofthis pathway, whereas epidermal growth factor, EGF, causes only
a tranient activation ofthis pathway (29 30). Recently, it has been shown that the
protein Rapl mediates the sustained activation of the pathway (64). It was initially
thought that sustaied activation of the Ra-ERK pathway was sufficient to differentiate
PC12 cells (65). However, this theory relied heavily on overexpression studies. In
addition, the discover ofNGF-stimulated Ra-independent signaling events in PC12
cells has modified these earlier interpretations. It is now thought that the Ra-ERK
pathway is necessar but not suffcient for NGF-induced differentiation ofPC12 cells
(29 66).
The role of the p38 and JN pathways in PC12 differentiation also has been
analyzed. Initially, it was reported that p38 was not activated in NGF-treated PC12 cells
but rather was activated after NGF withdrawal (67). However, two more recent reports
show that p38 is acivated by NGF in PC12 cells (68 69). Moreover, p38 may play an
essential role in the differentiation ofPC12 cells (68). Also, expession of a
constituitively active MEK results in the activation of p38 , demonstrating cross talk
between the Ras-ERK pathway and the p38 kiase pathway (68). The p38 kinase
pathway may also synergize with the Ras-ERK pathway in order to transmit signals to the
nucleus. This is the case in PC12 cells with the activation of the transcription factor
CREB (69). Finally, the JN pathway does not appear to be induced by NGF in PC12
cells and therefore is not thought to playa role in NGF-induced differentiation ofPC12
cells (67 69).
The study of these pathways has inevitably led to the discover of varous inibitors
that block these pathways. For the Ra-ERK pathway, the inibitor PD98059 has been
used extensively to elucidate the involvement of this MA kinase cascade in varous
cellular processes (70 71). Recently, another inhibitor of the Ras-ERK pathway, U0126
has been introduced (72). PD98059 inibits activation ofMEK. U0126 inhibits MEK
activation and activity. PD98059 is more potent towards MEKI than MEK2 while
U0126 is equally potent towards both MEK isoform and is more potent than PD98059
(70 72). A potent and specific inibitor of the p38 kinase pathway, SB203580, has also
been developed. SB203580 is specific for p38-a.f3 and does not inhibit p38-y/o
(71 74). All of these drgs have been useful in elucidating the physiological
substrates of the respective kinases, as well as defining cellular processes dependent on
the MA kinase pathways (71 75) (Figue 1-5).
NH2
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Figue 1-5. Strcture of MAP kinase pathway inhibitors
Nitrc oxide as a cytostatic signal durg neuronal diferentiation
A large volume of work has been done to show that under various cellular
conditions nitrc oxide can induce p53 levels (76-78). In addition, it has been shown that
NO regulates proliferation in the iminal discs of developing Drosophila through the Rb
pathway (79 80). It has also been demonstrated that NOS levels are induced during
differentiation ofPC12 cells (81 82) and that this production of NO serves as a signal for
growth arest (83). Moreover, blocking NO production prevents cell cycle arest and,
thereby, prevents differentiation ofPC12 cells. Conversely, treating PC12 cells with
nitric oxide donors can inibit thymdine incorporation (83).
Thesis Q)als
Knowing that nitrc oxide is a facor in activating p53 and can sere as 
cytostatc agent durg neuronal differentiation we set out to do three things:
1. Link NO to the inducton of p53 and p21 W AFI durg neuronal differentiation.
2. Investigate the regulation of nNOS durg neuronal differentiation.
3. Provide a mechanism by which NO can elevate p53 levels.
CONTRIUTIONS
Durg the initial stages of my time in the Ross lab, I worked very closely with a
postdoc in the lab, W ojciech Poluha. Chapter II of this thesis is a manuscript on which
he is the fIrst author and I am second (84). I include this chapter for two reasons. First
the results from this paper serve as a framework for the rest of my work in the lab.
Second, I had a very active role in performng the experiments and preparation of the
mauscrpt. Wojciech and I worked together to obtain the results in figures 2-
4 and 2-7. In figure 2-1 and 2- , I did all of the cell culture and treatments and then
Wojciech took the cells from me and did staining or wester blots. For figure 2- , I
performed repetitions ofWojciech' s initial results. I also assisted Wojciech in his initial
luciferase experments in figue 2-4. Finally, I did the wester blot for figue 2-
The data presented in chapters m, IV and V of this thesis was performed by
myself with occasional assistance and advice from members of the Ross lab.
CHATER 
A NOVEL, NGF-ACTIV A TED P A THW A Y INOLVIG NITRIC OXIE, p53 and
p21WAFl REGULATES NEURONAL DIFFERENTIATION OF PC12 CELLS
Neuronal differentiation is closely linked to cessation of cell proliferation, but
how these states are connected remains a major unanwered question. Nere growth
factor (NGF) induces both cell cycle arest and differentiation for PC12
pheochromocytoma cells (35). These effects are associated with induction of nitric oxide
synthase (NOS) (81 83), the p53 tumor suppressor (48), and the p21 W AFI cyclin-
dependent kiase inhibitor (41,42 85). However, the relationship between these signaling
events, arest and differentiation is poorly understood.
Nitrc oxide (NO) is a regulatory molecule that influences may processes
perhaps, including neuronal proliferation and differentiation. NO is synthesized from
arginine by a famly of three NOS proteins , neuronal NOS (nNOS), endothelial NOS
(eNOS) and inducible NOS (iNOS) (86). In mature mals, NO acs as a
neurotranmitter, a regulator of blood pressure and a toxin for kiling pathogens. A role
for NO in the developing nerous system is plausible since nNOS is absent from
proliferating neuroblasts but is coexpressed with early makers of neuronal differentiation
(87 88). In Drosophila NOS is expressed in developing imaginal dics (79). Inbition
of NOS in larvae results in enhanced cell proliferation, and elevated NOS expression
stunts development. In rats , NGF enhances expression of nNOS by cholinergic neurons
ofthe basal forebrain (89). NGF treatment ofPC12 cells induces expression of all three
isoform of NOS (81 83), and inibitors of NOS block NGF-induced cessation of
proliferation and neurite extension for PC12 cells (83). Hence, NO acts as a regulator of
cell proliferation which, in tur, influences process outgrowth.
The tumor suppressor p53 may playa role in neural development, in addition to
its well established function as an inducer of apoptosis or cell cycle arest, following
cerain tyes of cell stress , including DNA daage (43). Mice lacking functional p53
genes have an unusually large number of birh defects, such as failure of neural tube
closure (47). In some mouse embryos, the absence ofp53 leads to exencephaly in which
overgrowth of neural tissue in the fore- and midbrain leads to abnormalities in cranial
development (90). This overgrowth probably results from excessive cell proliferation
rather than decreased cell death. Consistent with this role, a recent study found that p53
is required for NGF-induced neurte extension by PC12 cells (48).
p21 WAFI binds to and inibits cyclin-dependent kinases and induces cell cycle
arest at G1/S (36). p53 is a potent trancriptional activator for p21WAFl (36 46), but
expression of p21 W AFI also can be induced by p53-independent mechanisms (91-95).
In vivo expression ofp21WAFl is enanced as myoblasts differentiate into muscle cells
(96). p21WAFl is not expressed in the mitotic gerinal layer of the olfactory epithelium
but is expressed by olfactory neurons (96). We (41) and others (42 97) have reported
up-regulation of p21 W AFI expression in NGF-treated cell lines. We have demonstrated
that p21WAFl is required for surval of differentiating neuroblastoma cells (41), but
van Grsven et al. (85) have suggested that following differentiation ofPC12 cells
continued expression of p21 W AFI is not required to maintain their differentiated
fi 
phenotye. Hence, it may be that p21 W AFI plays its most important role durg
differentiation.
In this report, we provide the fist evidence for a connection between these NGF-
induced events. We find that nitc oxide (NO) activates the p21WAFl promoter
resulting in expression ofp21WAFl protein. This lin is parially dependent on p53 , a
potent, trancrptional activator for p21 W AFI (36). NO also is required for NGF-
induced expression of two makers associated with neuronal differentiation. Using a
PC12 line bearg an inducible expression vector for p21WAFl , we fid that induction of
recombinant p21 W AFI restores NGF-induced differentiation for cells treated with a NOS
inhibitor. These data demonstrate a signal transduction pathway that is acivated by
NGF, proceeds through NOS , p53 and p21 W AFI to block cell proliferation, and is
required for NGF-induced neuronal differentiation by PC12 cells.
Materials and Methods
Cell Culture
PC12 cells from Dr. David Kaplan (Montreal Neurological Institute) were
maintained in DMEM supplemented with 10% heat-inactivated horse seru 5% heat-
inactivated fetal bovine serum, and 100 p.g/ml ofgentamycin at 37 C under 5% CO
These cells were found to be mycoplasma-free by the direct culture method
(MYCOTRI, Ire Scientific, Santa Ana, CA). For PC12 cell differentiation, plastic
dishes were treated overnght at 4 C with 15 p.g/ml of rat tail collagen (Sigma Chemical
Co. , St. Louis, MO) and 15 flg/ml ofpoly- lysine (::300 000 Da, Sigma). The dishes
were rinsed with distiled water, and then PC12 cells were plated in defined medium, as
described (98), and treated with 100 nglml ofNGF (2. 5 S, Bioproducts for Science
Indianapolis, IN). Afer 3-4 days oftreatment, cells with neurites at least five cell
diameters long were scored as positive.
NOS Inibitors
N-nitro-L-arginine methyl ester (L-NAM) competes with arginine for binding to
all three isoform of NOS and blocks enzatic activity (86). In these studies, we used
20 mM L-NAM and the same concentration ofthe inacive enantiomer, D-NAM, as 
control. L- NAM used at this concentration is thought to be specific for NOS and with
little effect on PC12 metabolism, growth rates and NGF-induction of imediate early
genes (83).
Preparation of a p21 W AF1 Inducible Cell Line
We prepared a PC12 line bearng an inducible expression vector (LacSwitch
Stratagene, La Jolla, CA) for p21WAFl. In this system, maalian cells are tranfected
with both a Lac-repressor -expressing vector and a lac-operator -contaiing p21 W AFI
vector. Expression ofp21 WAF 1 occurs within 48 hrs following addition of25 mM
isopropyl thio B-galactoside (IPTG).
J. Earhear and R. Pittman (University of Pennylvania School of Medicine)
prepared the p21 W AFI plasmid for these experents. In bref, the protein-encoding
portion ofthe p21 W AFI cDNA was insered into the pOPRSVl plasmid (Stratagene)
which includes a neomycin resistance gene. Expression of p21 W AFI is drven by a Rous
sarcoma virus promoter but, in the absence ofIPTG, is suppressed by adjoining lac
operator sites. Plasmid p3' SS which has the lac repessor gene under control of a
Cytomegalovi early promoter also was from Stratagene and was used without
modification.
PC12 cells were transfected with the p3' SS Lac repressor plasmid, using the
cationic detergent Lipofectin (Gibco). Plasmid DNA (6-7 J.g per 25-cm2 flask) was
diluted in 100 J.l ofDMEM medium (serum-free). At the same time in a second tube, 20
J.l of 1 mg/ml Lipofectin was diluted with 100 J.I ofDMEM. Afer a 30 mi incubation
at room temperature, the two solutions were combined and incubated for an additional 15
min at room temperature. This mi was then diluted with 2.5 m1 of complete medium
including serum, added to a 25-cm2 tissue culture flask containing about 3 x 10 cells and
incubated overnight at 37 C. The resulting cells were selected for 14 days with medium
containing 125 J.g/ml ofhygromycin. This mass culture was derved from about 20
different hygromycin-resistant colonies. These cells were then tranfected by the same
procedure with thepOPRSVl p21WAFl plasmid beargthep21WAFl cDNA and
selected for 14 days with 100 J.g/ml ofG418. The mass culture from the second
tranfection was derived from about 30 different G418-resistant colonies. The
morphology and rates of proliferation of these cells were not obviously affected by the
tranfections.
Western Blottg
Following treatment with NGF and NO drgs, cells were extacted as descrbed
(46). These samples ( 40 flg of protein/lane) were boiled under reducing conditions
subjected to electophoresis on a 12.5% polyacrylamide gel and electrotranfered to an
Immobilon-P membrane (Milipore, Bedford, MA). Residual proteins in the gel were
stained with Coomasie blue to confi even loading of the gel The membrane was
blocked for 1 hr with 10% powdered milk in 0.2% Tween- , Tris-buffered saline and
then incubated with 2 flg/ml ofanti-p53 monoclonal antibody Pab- 1801 (Oncogene
Science, Cambridge, MA), 1 flg/ml of rabbit anti-p21WAFl antibody C-19 (Santa Cruz
Biotechnology, Santa Cruz, CA) or 35 flg/ml of anti-nicotinic acetylcholine receptor
(nAChR) monoclonal antibody mab35 (99). Imunoreactive proteins were detected with
horseradish peroxidae-conjugated seconda antibodies (Amersham, Arlington Heights
IL) and a chemiluminescence reagent (100). The films were scaned with a Hewlett
Packard Scanet 3c. Brightness and contrast were adjusted with Photoshop, mang the
same adjustments for each band. Montages were assembled with CoreIDaw, using only
imaes from the same experiment and fim.
Diaphorase and Immunostaining
Cells were fixed for 10 mi at room temerature with 4% paraformldehyde in
PBS and immunostained with 1 flg/ml ofanti-p21WAFl rabbit antibody C-19 and then a
rhodae-conjugated seconda antibody. The cells were then incubated with 1.
mgml ofNADPH, 0.25 mgml of nitro blue tetrazolium and 0. 1 M Tris HCl for 4 hr at
C (101). Samles were mounted in Citifluor (Ted Pella Inc. , Reading, PA) and were
viewed with a Zeiss Axioskop microscope and a 25X oil imersion objective lens , using
bright field and fluorescence optics to detect diaphorase and p21 W AFl , respectively.
For detection of neuronal markers, cells were fied for 10 mi with 95%
methanol, 5% acetic acid at - C. The samples were stained with 35 Ilg/ml of
monoclonal antibody mab35 against the a. subunit of the nicotinic acetylcholine receptor
(nAChR) (99) or ascites diluted 1 :200 from hybridoma MAIB-4 directed against
microtubule-associated protein IB (MAIB) (102 103). These antibodies were diluted
with 0.3% BSA, 0.2% Tween 20 in Tris-buffered saline. Both ofthese markers are
expressed during development, although the time of initial onset is earlier for MAIB
(104).
Micrographs were recorded with Koda T -MA 400 fim and digitized with a
Nikon Coolscan. Brightness and contrast were adjusted with Adobe Photoshop, and
montages were assembled with CorelDaw. The figures were prited using a Koda
Colorease PS prnter on Koda Extather XLS paper.
p2lW AFl Promoter Actvity
PC12 cells were treated for 60 hours with or without NGF, L-NAM, or D-
NAM. Then, using Lipofectin as descrbed above, they were cotranfected with
promoter constructs WW-Luc or DM-Luc (36) (6 1lg/25-cm
2 flask) and B-galactosidase
plasmid pCHII0 (6 1lg/25-cm2 flask). The 2.4 kb WAFI promoter region was obtaied
by PCR and cloned into pBluescrpt KS(+) to yield plasmid WW-Luc. DM-Luc which
lacks the p53-binding element was obtaied by digesting WW-Luc with Sac1 and
recircularation. After 16-20 hrs, cells were extracted for 15 min at room temperature
with Cell Culture Lysis Reagent (Promega)(25 mM Tri-phosphate, pH 7. 2 mM
dithiothreitol, 2 mM 1 , 2-diaminocyclohexane N, N, N' , N' tetraacetic acid, 10%
glycerol and 1 % Triton X- I 00). These extracs were clarfied by centrifugation, stored at
- 70 C and then used immediately after thawing. Mixtres of 20 l of cell extract and 100
l ofLuciferase Assay Reagent (20 mM tricine, 1.07 mM (MgC03)4Mg(OHh' , 2
mM MgS04, 0. 1 mM EDT A, 33.3 mM dithiothreitol, 270 M Coenzyme A, 470 
luciferin, 530 M ATP, pH 7. 8) were immediately placed in Model N Luminometer
Analyzer (Packard) and luciferase acivities were measured.
galactosidase activities were measured using a kit ftom Promega. Assay 2x
buffer (120 mM Na HP04, 80 mM NaH P04, 2 mM MgCh, 100 mM B-mercaptoethanol
1.33 mgml of o-nitrophenyl- galactopyranoside) was mixed with an equal volume
(100 l) of cell extract. Samples were incubated overnght at 37 , and the reaction was
stopped by addition of 50 l of 1 M Na C03. Optical densities at 420 nm were measured.
Luciferase activities were normalized with B-galactosidase activities to eliminate any
differences in transfection effciencies.
Results
Using NGF-treated PC12 cells as a model system, we tested the relationship
among several signaling events that occur durng neuronal differentiation. We found that
the NOS inhibitor, L-NAM, but not the inactive enantiomer D-NAM, inhibits NGF
induced neurite extension by 73 :r 15% (mean:r S. , n = 6), in agreement with Peunova
and Enkolopov (83).
We assayed expression of two makers associated with neuronal differentiation.
As judged by immunofluorescence microscopy, MAIB (105 106) is upregulated by
NGF (Fig. 2-1). For this experiment, untreated PC12 cultures showed 12:r 1% of cells
positive for MAIB, but NGF-treated cultues showed 87:r 3% cells positive. 
NAME, but not D-NAM, reduced this NGF-induced increase in MAIB expression (D-
NAM+NGF-treated cells, 88 :r 4% positive; L-NAM+NGF-
treated cells, 14:r 2% positive). Averaging 3 experiments, L-NAM inhibited NGF
induction ofMAIB-positive cells by 85:r 10%. The pattern of expression for nAChR
closely resembled that for MAIB (107) (micrographs not shown).
By Wester blotting, we obsered the same patter of expression for nAChR (Fig.
2). Averaging 3 experiments, the relative intenities of the nAChR bands for control
NGF, NGF+D-NAM, NGF+L-NAM, and L-NAM were 1.0 6:r 0.2 7:r 1.6
:r 0.4, and 0. 8 :r 0. , respectively. The anti-MAPIB antibody does not detect MAIB
protein by Wester blotting. Hence, NO, like cell cycle arest, is required for NGF-
induced differentiation.
We then analyzed the role of NO in regulating expression of p53 and p21 W AFI
(41 42,48 85). As judged by scaning densitometry, NGF induced accumulation of p53
and p21W AFI by 7. 1 :r 4.3 fold and 4.7:r 1.1 fold (n=3), respectively, compared to
levels in untreated cells (Fig. 2-3). L-NAM, but not D-NAM, inibited NGF-induced
accumulation ofp53 by 87:r 7% and p21W AFI by 61 :r 7%. This is the first report that
Figure 2-1. NGF-induced expression ofMAPlB is dependent
on NO. Cells were immunostained for MAPIB and examined
by immunofluorescence microscopy. Panel A , no addition;
panel +NGF (100 ng/ml); panel C, +NGF + D-NAME
(20 mM); panel D , +NOF + L-NAME (20 mM). Bar = 25 J..
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Figure 2-2. NGF-induced expression of nAChR is dependent on NO.
PC12 cells were treated as in Fig. 1 and extracted for Western blottig.
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Figure 2-3. NOF and NO enhance expression ofp53 and p21 WAFt.
Cells were treated as in Fig. 1 and then extracted. p53 and p21 W AFI
were assayed by Western blotting.
, at physiological levels, acts as a second messenger to enhance expression of p53 and
p21 , although it was reported that treatent of cells with NO donors induces
accumulation ofp53 (77 108- 113).
To evaluate fuher the relationship between NO and p21WAFl expression, we
transfected PC12 cells with a p21 W AFI promoter-luciferase reporter construct (WW-
Luc (36)) and found that treatment with NGF significantly enhanced the activity of the
p21WAFl promoter (p:S 0.0001 , Students-t test)(Fig. 2-4). This response was inibited
by L-NAM, but not by D-NAM. The parallel regulation of p21 W AFI promoter
activity and p21 W AFI protein levels (Figs. 2- 4) suggests that NGF increases
p21 W AFI levels by an NO-dependent increase in p21 W AFI promoter activity.
To detere whether NGF regulates p21 W AFI promoter activity via p53 , a
potent trancrptional activator of p21 W AFI (36), we utilized a truncated promoter
lacking the p53 binding site (DM-Luc (36)). Cells tranfected with this shorter constrct
gave substantially reduced responses to NGF (Fig. 2-4). Therefore, trancriptional
activation by p53 is a major mechanism by which NGF induces p21 W AFI expression.
However, there was significant activation (p:S 0.0001) of the shorter promoter construct
indicating a second mechanism independent of the p53 binding site.
We also assessed the relationship beeen NOS , p21 W AFI and neurte extension
for individual cells. We double stained PC12 cells for diaphorase acivity and p21 W AF1.
Diaphorase staining allows visualization of NOS enatic acivity, resulting in colored
cells that can be detected by brght field light microscopy (114 115). This method is
specific for NOS because other diaphorases are inactivated by fixation with
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Figure 2-4. Activation of p21 W AFl promoter by NGF and NO. The diagam shows the
promoter-reprter constrcts WW-Luc and DM-Luc. The p53 binding site present in
WW-Luc, but not in DM-Luc, is shown as a filled circle. Cells were treated with drgs
cotranfected with the promoter-reporter plasmids and a f3-galactosidae plasmid, and
then luciferase and f3-galactosidae activities were measured. Luciferase activities were
normlized with f3-galactosidae activities to elimiate small differences in tranfection
effciencies. Six experents were averaged and reported as the ratio of treated cells
relative to untreated WW-Luc and DM-Luc tranfected cells , respectively. Errors were
propagated as descrbed (116).
paraformldehyde. p21 W AFI was detected by immunofluorescence microscopy, using
an anti-p21 WAFI antibody. For untreated cultures, few PC 12 cells displayed diaphorase
staining, p21 W AFI immunoreactivity or neurtes (Fig. 2- , C, E). NGF treatent
increased the percentages of cells with diaphorase activity (92%), p21 W AFI
immunoreactivity (85%) and neurites (77%)(Fig. 2- , D, E). The staiing for
p21 W AFI was almost exclusively nuclear, in ageement with other studies (46 117).
To test the role ofp21 W AFI in NGF-induced differentiation, we prepared a PC12
line bearg an inducible p21 W AFI expression vector (Fig. 2-6). This line differentiated
in response to NGF, in the same maer as the parental PC12 line, and L-NAM reduced
neurte extension (Fig. 2- , D, E). However, induction of p21 W AFI expression with
IPTGrestored NGF-induced differentiation ofL-NAM-treated cells (Fig. 2-6B).
Addition ofIPTG alone had no effect on neure extension (not shown), but IPTG did
reduce proliferation, as judged by BrdU labeling, by 58 :I 5%. IPTG did not enhance the
effect ofNGF (Fig. 2- , E). We also noted that p21WAFllevels induced by IPTG (320
:I 30% relative to untreated cells) were similar to those induced by NGF (250:1
20%)(Fig. 2-7). Hence, p21 W AFI is the functionally important target of the NGF-NOS
pathway, but p21WAFl , like NO, is not suffcient by itself for PC12 differentiation.
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Figure 2-5. Differentiated PC12 cells express NOS and p21 W AFI.
PC12 cells in defined medium were treated for 3 days without
(panels A and C) or with 100 nglml NGF (panels B and D). The
cells were double stained for diaphorase activity (panels A and B)
and p21WAFl (panels C and D). Averages and S.D. values from
three independent experiments are shown in panel E. Bar = 10 
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Figure 2-6. Role ofp21 W AFI in NGF-induced differentiation.
PC 12 cell s bear ng an i nduci bl e p21 WAFI ex pressi on vector
were treated for 3 days with 100 ng/ml NGF (panel A),
NGF + L-NAME (20 mM) + IPTG (25 mM) (panel B),
NGF + IPTG (panel C), or NGF + L-NAME (panel D).
Panel E, quantification of neurte extension (average:f S.
Bar = 30 fJm.
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Fig. 2-7. Expression ofp21WAFl induced by NGF and IPTG. PC12
cells bearng an inducible p21 WAFI expression vector were treated
for 3 days with no addition, 100 ng/ml NGF, or 25 mM IPTG.
Expressi on of p21 WAF 1 was assayed by Western blottig.
Discussion
The major fiding of this study is a novel, NGF-activated signal tranduction
pathway that regulates neurite extenion. NGF binds to its receptors and induces
expression of NOS , perhaps by activating MA kinases (58) and the trancrption factor
NF-KB (118 119), which are associated with NOS expression (120-122). In ongoing
studies (Bulseco and Ross, not shown), we have found that TrkA can induce NOS
expression but have not yet assessed the role of the other NGF receptor, gp75. NO , in
tur, raises levels ofp53 , a protein required for NGF-induced differentiation ofPC12
cells (48). p53 protein activates transcrption ofp21WAFl by binding to a p53 binding
site in the p21 W AFI promoter, but trancrption of p21 W AFI also is acivated by a
second mechanism which is not dependent on the p53 binding site and might involve the
AP2 trancriptional activator protein (123) or the p300 trancriptional co-activator protein
(124). The p21 W AFI protein is known to block the cell cycle at the G1/S transition. As
judged by neurte extension and expression of neuronal makers, neuronal differentiation
occurs when the NGF-NOS-p21WAFl-cytostasis pathway is activated in conjunction
with the MA kinase, SNT and, perhaps , other NGF-regulated pathways (29).
For this pathway, the molecular targets of NO are not known, but we can suggest
several possibilities. The best characterized target for NO is guanylate cyclase (87). NO
activates guanylate cyclase, raising levels of cGMP and activating the cGMP-dependent
kinase. The relevance of guanylate cyclase to NGF- induced differentiation is suggested
by the increase in cGMP levels in PC12 cells following treatment with NGF (125). 
also reacts with ribonucleotide reductase, an enze required for nucleotide biosynthesis
and cell proliferation (126). In addition, high levels of NO dae DNA and, thereby,
induce expression of p53 (77). It is unlikely NGF induces suffcient levels of NO to
damae DNA, but we cannot exclude it from consideration.
The effects of NO include elevated levels ofp53 (77 108-113), a protein required
for NGF-induced neurtogenesis ofPC12 cells (48). It is possible that p53 activity is
additionally modified by other mechanisms. p53 is regulated by association with a
varety of other proteins such as mdm-2 (43). Since p53 is subject to redox regulation
and has free cysteines which might react with NO (127 128), p53 itself might be an NO
target. p53 activity is regulated by phosphorylation by casein kinase IT, protein kinase C
and cyclin-dependent kiases (43). In addition, subcellular localization plays an
important role in p53 function. NGF treatent ofPC12 cells induces tranlocation of
p53 from the cytoplasm to the nucleus (48).
In a recent study, it was reprted that NGF-induced expession of p21 W AFI is
p53-independent (124). In contrast, we find that activation of the p21WAFl promoter
occurs by two mechanisms. The first is initiated by binding of p53 to a site in the
p21 W AFI promoter. The second is independent of this p53 binding site. These
contradictory fidings may be related to differences in culture conditions which affect
both the extent of differentiation and the expression of cell cycle-associated proteins. For
measurements ofp21WAFl promoter activity, we treated the PC12 cells for three days in
defmed medium which considerably speeds both NGF-induced differentiation (98) and
induction ofp21 W AFI (129). The other group treated their cells for only two days in
ser-containing medium. Hence, at the time of the promoter assay, the cells in our
experiments were probably more differentiated than those in the other study. In addition
to the degree of differentiation, the cultue medium may considerably affect expression of
cell cycle-associated proteins. NGF induces expression of p21 W AFI in defied medium
(this study and (129)) or in the presence of serm (42 97) but not in DMEM lacking
both serm and growth factors (85). Furher studies are required to resolve these
differences, but ultimately we feel that p53 wil be shown to playa role in this pathway,
since p53 is required for NGF-induced neurte extension by PC12 cells (48).
NO leads to p21 W AFI induction but also regulates the activities of other enzes
and the expression of additional gene products (87). Which of these events is relevant to
cell cycle arest and neurte extension? To anwer this question, we prepared a PC12 line
with an inducible p21 W AFI expression vector. Blocking NOS with L- NAM inhibits
neurte extension, but induction of p21 W AFI with IPTG restores the response.
Furthermore, the levels of p21 W AFI induced by NGF and by IPTG are similar, so it is
unlikely that our conclusion is based an arifact of overexpression. Hence, the lesion in
the pathway caused by L-NAM is complemented by IPTG-induced p21 W AFl , and we
conclude that p21 W AFI is a biologically relevant downstream product.
These studies have been cared out using PC12 cells which are the most
commonly used model for NGF-activated signal tranduction and differentiation.
However, these findings are relevant to other neuronal cell types, both in vitro and 
vivo. For examle, neuroblastoma a pediatric tumor which probably results from
blocked differentiation durng gestation, has a high rate of spontaneous regression in
which the tumor decreases in size and, in some cases, disappears. This favorable
outcome is thought to be due to differentiation of tumor cells and is correlated with
expression ofTrkA (130- 132). In addition, nearly all neuroblastoma have functional
p53 (133- 135) and p21WAFl (136) genes. Hence, neuroblastoma have the molecular
components required for the NGF-NOS-p21WAFl pathway. We have found that NOS is
required for both expression of p21 W AFI and surival of differentiating neuroblastoma
SH-SY5Y cells (41) (not shown). This cell culture model suggests that the NGF-NOS-
p21 W AFI pathway may playa role in spontaneous regression of neuroblastoma.
This signal tranduction pathway discovered in PC12 cells probably also plays a
role in norml development of the nervous system. Neurotrophin, in paricular
neurotrophin- , may be signals that termate neuroblastic proliferation (137 138).
Likewise, a role for NOS in controlling neuroblastic proliferation is suggested by the
expression of NOS durig neuronal differentiation (88 139). Disruption of the NGF-
NOS-p21 W AFI pathway may have adverse consequences for development. Mice
lacking p53 genes have an unusually large number of birh defects, including failure of
neural tube closure (47) and exencephaly in which overgrowth of neural tissue in the
fore- and midbrain precludes norml formation ofthe cranium (90). This overgrowth
probably results from excessive cell proliferation rather than decreased cell death. 
Drosophila inhibition of NOS results in excessive proliferation durg development (79).
The NGF-NOS-p21 W AFI pathway also may playa role in the regulating phenotye of
postmitotic neurons. NGF induces expression of both NOS and choline acetyltranferase
in developing basal forebrain neurons (89).
T'-
Finally, the pathway may be relevant to neuronal responses to injur. Following
injur ofCNS neurons, both NOS and p53 are induced (140- 142). Although speculative
it would be interesting to deterne if p21 W AFI also is induced. In addition to cyclin-
dependent kiases, p21 W AFI inibits casein kinase-2 (143) and stress-activated 
kinases (144). Activation of JNK kinases is associated with cell death resulting from
neurotrophin deprivation (67). By modulating these kinases, p21 W AFI might playa role
in injur-induced responses. Hence, this model defines a key pathway required for NGF-
induced differentiation ofPC12 cells and serves as a prototye for the analysis of
additional pathways that regulate cell proliferation durig differentiation, the course of
neurl tumors and responses to injur and other stimuli in matue neurons.
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THE RAS-MA KIASE PATHWAY IS REQUID FOR THE INUCTION OF
NEURONAL NITRIC OXIE SYNHASE IN DIFERENTIATING PC12 CELLS
Introduction
MA kinase pathways are key regulators of may cellular processes. In maals,
there are three wen-characterized MA kinase pathways (57). The Ras-Raf-MEK
pathway is important for mitogenic, differentiation and surval responses (58-60). The
other two MA kiase pathways are involved in stress and apoptotic responses and are
referred to as the JN pathway and the p38 kiase pathway. JN were isolated and
charactered in par by their ability to phosphorylate the transcription factor c-Jun and
are strongly activated by stress-inducing stimuli (61 62). The third MA kinase, p38 , is a
homolog ofthe yeast HOGI. In maalian cells, the p38 kinase pathway is induced by
LPS and high osmolarity (59 62). Hence, the MA kinase pathways act as conduits
conveying informtion from the cell surface to the cytoplasm and nucleus.
In PC12 cells, the Ras-ERK pathway plays a crtical role in tranmitting signals from
nerve growth factor (NGF). Upon binding ofNGF to its receptor TrkA, adaptor
molecules Shc, Grb2, and Sos recrit and activate the small G protein Ras (29). The
activation of Ra initiates a kinase cascade that proceeds from Raf to MEK to ERK. 
PC12 cells , NGF elicits a sustained activation ofthis pathway, whereas epideral growth
factor causes only a transient activation of this pathway (29 30). Recently, it has been
shown that the protein Rapl mediates the sustained activation ofthe pathway (64). It was
initially thought that sustained activation of the Ras-ERK pathway was sufficient to
differentiate PC12 cells (65). However, this theory relied heavily on overexpression
studies. In addition, the discover ofNGF-stimulated Ras-independent signaling events
in PC12 cells has modified these earlier interpretations. It is now thought that the Ras-
ERK pathway is necessar but not suffcient for NGF-induced differentiation ofPC12
cells (29 66).
The role of the p38 and JN pathways in PC12 differentiation also has been
analyzed. Initially, it was reported that p38 was not activated in NGF-treated PC12 cells
but rather was actvated after NGF withdrawal (67). However, two more recent reprts
show that p38 is activated by NGF in PC12 cells (68 69). Moreover, p38 may play an
essential role in the differentiation of PC 12 cells (68). Also , expression of a
constitutively active MEK results in the activation of p38 , demonstrating cross talk
between the Ra-ERK pathway and the p38 kiase pathway (68). The p38 kinase
pathway may also synergize with the Ra-ERK pathway in order to tranmit signals to the
nucleus. This is the case in PC12 cells with the activation of the trancrption factor
CREB (69). Finally, the JN pathway does not appear to be induced by NGF in PC12
cells and therefore is not thought to playa role in NGF-induced differentiation ofPC12
cells (67 69).
The study of these pathways has inevitably led to the discover of varous inhibitors
that block these pathways. For the Ras- ERK pathway, the inibitor PD98059 has been
used extensively to elucidate the involvement of this MA kinase cascade in varous
cellular processes (70 71). Recently, another inibitor of the Ra-ERK pathway, U0126
has been introduced (72). PD98059 inhibits activation ofMEK whereas U0126 inibits
both MEK activation and activity. PD98059 is more potent towards MEKI than MEK2
while U0126 is equally potent towards both MEK isoform and is more potent than
PD98059 (70 72). A potent and specific inibitor of the p38 kiase pathway, SB203580
has also been developed. SB203580 is specific for the ubiquitously expressed a and 
isoform ofp38. (71 145). These drgs have been useful in elucidating the
physiological substrates ofthe respective kinases, as well as defining cellular processes
dependent on the MA kinase pathways (71 75).
Nitric oxide (NO) perorm a multitude of physiological and pathological functions in
the nerous system. NO in cells is produced by nitrc oxide synthase (NOS) of which
there are three isotyes; nNOS or bNOS (neuronal or brain NOS), eNOS (endothelial
NOS) and iNOS (inducible NOS). In the nerous system, NO is involved in learing and
memory, neurotranmitter release, development and neuronal dae or degeneration
(3). It has also been postulated that NOS levels are induced durg differentiation of
PC12 cells by NGF. The nNOS gene includes two promoters, 5' 1 and 5'2. NGF
induction ofnNOS is due to activation of the 5' 2 promoter (146). Although there is one
report of nNOS induction by the mitogen
, epiderl growth factor (EGF) (82), we (daa
not shown) and others (83 146) have not detected nNOS induction by EGF. The
production of NO in response to NGF seres as a signal for growth arest (83). Blocking
NO production prevents cell cycle arest and, thereby, prevents differentiation ofPC12
cells. This cytostatic signal of NO appears to act through p53 and the cyclin-dependent
kinase inhibitor p21WAFl (84). In addition, it has been shown that NO regulates
proliferation in the imaginal discs of developing Drosophila through the Rb pathway
(79 80).
We set out to investigate which MA kinase pathways are necessar for the induction
ofnNOS in NGF-treated PC12 cells. We find that the Ra-ERK pathway is necessar for
the induction of nNOS protein and enzmatic activity. The p38 pathway and the 
pathway do not appear to be required for this induction. Finally, we resolve conflicting
results obtained with the MEK inibitors, U0126 and PD98059. We find that U0126
inhibits NOS induction much more effectively than PD98059 because in PC12 cells
U0126 inibits the Ras-ERK pathway much more effectively than PD98059.
Materials and Methods
Cell culture
Rat pheochromocytoma (PCI2) cells were a gift from David Kaplan. Cells were
grown at 37 C and 5% CO in DMEM supplemented with 10% FBS and 5% donor horse
serm (35). Treatments with NGF (100 ng/ml) were performed in flasks coated with
collagen (15 flg/ml) and poly- lysine (15 flg/ml). For experiments with various kinase
inibitors, cells were pretreated with the drgs for 30-45 minutes before the addition of
NGF. For differentiation ofPC12 cells NGF and drgs were replenished every 48 hours.
f."
Adenovises and Infection Protocol
Virs-containing cell lysates (DNRas; Ser 17 to Asn, and XRaf; trncated at
amio acid 257 and Cys 168 to Ser) were prepared as described (60). Cells were infected
with virus-containing lysates in a minimal volume of media for 1 hour at 37 C. Growth
media was then added to increase the volume. Twenty-four hours after infection, the
media containing the adenovis was removed and replaced with fresh growth media.
Infection of cells with a MOl of 150 did not produce significant toxicity.
Materials
NGF (2.5 S) was purchased from Bioproducts for Science. PD98059 was
obtaied from New England Biolabs. U0126 was purchased from Promega. SB203580
and the NOS assay kit were purchased from Calbiochem. TRI reagent for total RNA
preparation was from Molecular Research Center, Inc. RT PCR kit was purchased from
Perkin Elmer. Monoclonal Anti-NOS-Brain (nNOS) antibody was purchased from
Sigma and Phospho-p44/42 MA Kinase antibody was from New England Biolabs.
Anti-MA kinase antibody (CI4) was from Santa Cru. Arginine, L-f2, was
purchased from New England Nuclear.
Western blots
To prepare total cellular extracts cells were removed from the flasks with HBSS +
EDTA and collected by centrifugation. After the superatant was removed cells were
resuspended in lysis buffer (10 mM Tris pH 7.4, 1% SDS, 1 mM PMSF and 5 flg/ml
aprotinin). An equal volume of2X samle buffer (250 mM Tris-HCl pH 6. 4% SDS
10% glycerol, 0.006% bromophenol blue and 2 % f3-mercaptoethanol) was added to 25
g of total protein, the samles were boiled and then separated by SDS-PAGE. Proteins
were then electrophoretically transfered to PVDF and the membranes were blocked with
10% milk in TTBS (0.2% Tween-20) for one hour at room temperature. Prmar
antibody incubations were for one hour at room temperature using the appropriate
dilutions (monoclonal nNOS 1:3000, monoclonal phospho-p44/42 MA kinase 1: 1000
and anti-p44/42 MA kinase 1: 100). Membranes were washed for thiry miutes with
three changes, and the seconda antibody incubation (anti-mouse horseradish
peroxidae-conjugated from Amersham 1: 1500) was for one hour. After washing
expression was detected using enhanced chemilumiescence (100).
Neurte extension
Cells were plated on collagen and poly- D-lysine coated 25-cm2 flasks at 1. 3 x 10
cells per flask and pictures were taken after 2, 4 and 6 days. Cells with extensions longer
than two cell diameters were scored as positive for neurites.
NOS assay
NOS assays were performed as detailed in the Nitric Oxide Synthase Assay Kit
from Calbiochem. Cells were collected, frozen in liquid nitrogen and then resuspended
in IX homogenization buffer (25 mM Tris-HCl, pH 7.4, 1 mM EDTA and 1 mM EGTA).
Extacts were tested in the presence of 0. 6 mM Ca ++, using 1 00 g of protein per samle
and 1 f.Ci of -argiine per assay. Arginine concentration was 25 f.M. Reactions
were carred out for thiry minutes at C. Assays were linear for both time and PC12
cell extract concentration (data not shown). Citrlline was then separated from arginine
with equilibrated ion-exchange resin and the radioactvity in the flow-through was
deterned by scintilation counting. Counts for negative control samples , no lysate or
lysate treated with the NOS inhibitor -nitro-L-arginine methyl ester (L-NAM) (
000 cpm/ experment), were subtacted and resuhs were presented as cpm/ 100 f.g of
lysate.
RT PCR
For RT PCR experiments , total RNA was prepared using TR reagent. 1 fJg of
total RNA was used to prepare cDNAs, using random hexamer primers. For the PCR the
nNOS primers were 5' AAG CAG TCA GAT GG TCT A 3' (forward primer) and 5'
TCT GTA GCG GTA TTC ATT CT 3' (reverse primer), which generates a 551 base pair
product. The PCR conditions were 92 C for 1 miute (denaturng step), 50 C for one
minute (anealing step), and C for one miute (extension step) for 30 cycles followed
by a fial 10 minute 72 C extension step. For G3PDH, primers were 5' GTC AAC GGA
TTT GGT CGT ATT 3' (forward primer) and 5' AGT CTT CTG GGT GG AGT GAT
3' (reverse primer), which generates a 540 base pair product. PCR conditions were 4
minutes at 95 C followed by 25 cycles of 45 seconds at 95 o , 45 seconds at 56 C and
one minute at 72 C. A final 10 minute 72 C extension step was included. PCR products
were resolved on 1.2 % agarose gels.
Results
Ras is requied for induction ofnNOS RNA, protein and NOS activity
In PC12 cells, NGF induced nNOS at the RNA level, as judged by RT PCR (Fig
1A). We also found that nNOS protein (Fig 3-1B) and NOS activity (Fig. 3-1C) were
induced in PC12 cells treated with NGF. By four days the induction of NOS activity was
statistically significant (p .c .001). The induction of nNOS mRA, protein and NOS
activity are in ageement with earlier experents (82 146). We failed to see an
induction of iNOS or eNOS by wester blots (data not shown), which is in ageement
with earlier findings (82).
To test the possibility that the Ra-ERK pathway is necessar for nNOS
induction, we compared PC12 cells with cells infected with an adenovis that expresses
a dominant negative Ras (60). The domiant negative Ra 17N functions by binding more
tightly to Ras-specific GEFs than does norml Ras and thereby, preventing activation of
endogenous Ra. RaI7N, in tu, canot bind to downstream targets even when bound
to GTP (147). As previously reported (60), we found that this dominant negative
adenovirus blocks differentiation ofPC12 cells but has no effect on surval or
proliferation (data not shown). At a MOl of 140, PC12 cells infected with the DNRas
virus showed greatly reduced induction of nNOS RNA, protei or activity when treated
with NGF for six days (Fig. 3- , B and C). The residual NOS activity in Fig. 3-2C may
be due to incomplete infection of these cultures. We estimte that 80-90% of cells are
Days
NGF
nNOS
PC12
G3PDH
Days
NGF
PC12
500
400
:I 300
200
100
Days
NGF
Figure 3-1. nNOS is induced at the RNA, protein and activity levels. Cells were treated
with or without 100 ng/ml ofNGF (- or +) for the indicated number of days. (A) RT PCR
was performed on PC12 cells. The media and NGF were replenished ever 48 hours. At
the indicated times total RNA was prepared and used for RT PCR (1 flg oftotal RNA per
reaction). PCR was cared out using primers specific for nNOS or the housekeeping
gene G3PDH. (B) Wester blots were performed using total cellular extacts ofPC12
cells. This Wester blot is repesentative of at least three experiments. (C) NOS assays
performed after 2 , 4 and 6 days ofNGF treatent are presented as cpm x 10 /100 Ilg of
lysate and are measured as a mean :i SEM (n = 9). Samples with no extract or extracts
treated with 1 mM L-NAM were used as negative controls. Extacs from untreated
cells were always within 5-10 % of these two negative controls.
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Figue 3-2. Ras is required for the induction of NOS. (A) After six days oftreatment RT
PCR was performed on untreated (UN, NGF-treated and NGF-treated DNRas (MOl
140) infected PC12 cells. RT PCR was performed for nNOS and the housekeeping gene
G3PDH. (B) Wester blots for nNOS were perormed on untreated, NGF-treated, NGF-
treated DNR infected and NGF-treated control virus Xraf infected PC12 cells after 6
days of treatment. These Wester blots are representative of three independent
experments. (C) NOS assays comparg NGF and NGF-DNRas infected PC12 cells after
6 days oftreatment are presented as least three experents. (C) NOS assays performed
' I
after 6 days ofNGF treatent are presented as cpm x 10 /100 Ilg of lysate and are
measured as a mean:! SEM (n = 6).
infected (60)( daa not shown). Thus , we have demonstrated that a fuctional Ras is
required for the production of nitric oxide in differentiating PC12 cells.
To control against adenovial specific effects, we perormed infections using an
adenovirus that expresses an inactivated Raf (XRt). XRfhas no kiase domain and
exhibits decreased Ra binding. It neither activates the pathway nor acts as a dominant
negative mag it an effectve negative control (148). Neurte extenion
by NGF-treated XRf-infected cells was indistinguishable from NGF-treated, uninfected
cells (data not shown). Additionally, infection with XRaf did not block nNOS induction
by NGF (Fig. 3-2B) or induce nNOS in the absence ofNGF (data not shown).
U0126, not PD98059, blocks nNOS inducton and NOS activity
Having shown that Ras is required for nNOS induction
, we tested whether
downtream effectors of the MA kinase pathway were necessar for this induction.
Previous work has shown the MEK inhibitor PD98059 is able to block the differentiation
ofPC12 cells (149-151). Recently, another MEK inhibitor, U0126, has also been used to
block the Ras-ERK pathway (72). We tested each of these drgs ability to block nNOS
induction. The PD98059 drg did not inhibit NGF-induced nNOS levels, even at
concentrations of 50 f!M (Fig. 3-3A). It is impractical to use this drug at higher
concentrations because it precipitates out of solution. U0126
, however, was ver
effective in blocking this induction at concentrations of 10 f!M to 50 f!M (Fig. 3-3A). We
also checked whether blocking the MA kinase pathway effected NOS activity. 50 f!M
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Figue 3-3. (A) Effect ofMEK inibitors on nNOS induction. Cells were pretreated with
carer alone, U0126 (10, 25 and 50 M) or 50 M PD98059 for 30 minutes before
addition of 100 ng/ml ofNGF. NGF, media and drgs were replenished every 48 hours.
(B) Effect ofSB203580 on nNOS induction. PC12 cells were pre-treated with increasing
concentrations ofSB203580 (10, 20 and 30 M) for 30 minutes and then NGF (100
ng/ml) was added. SB203580 and NGF were replenished ever 48 hours. After 6 days
extacs were prepared and Westers performed. This blot is representative of four
independent experiments. (C) Effect ofMEK and p38 inhibitors on NGF-induced NOS
activity. Cells were pretreated with 50 M ofPD98059, 50 M ofU0126 or 30 
SB203580 for 30 miutes before addition of 100 ng/ml ofNGF. NGF, media and drgs
were replenished ever 48 hours. After 6 days homogenates were prepared and citrulline
assays using 1 00 g of protein per sample were performed. Data are presented as cpm x
/100 g oflysate and are measured as a mean:l SEM (n = 6).
ofPD98059 was ineffective in blocking NGF-induced NOS activity six days (p = 0.450)
1,1
(Fig. 3-3C). U0126 at 50 M completely blocked NGF-induced NOS activity after six
days (Fig. 3-3C). These results were statistically significant (p': . 001). Simlar results
were obtained after four days (data not shown). The nNOS Western blots and the NOS
activity assays gave ver similar results: PD98059 has negligible effects on nNOS
induction while U0126 is a potent inhibitor ofnNOS induction.
p38 kiase does not regute nNOS inducton
Recently, it was reported that the p38 kinase pathway is involved in the
differentiation ofPC12 cells (68). We investigated whether the p38 inibitor, SB203580
would have any effect on neurte extension and induction of nNOS. Treatent with 
M SB203580 inhbited neurite extension by 38% (p':0. 01). In contrast, Fig. 3-3B shows
that SB203580 (10-30 M) did not inhibit the induction ofnNOS protein levels.
Similarly, 30 M SB203580 did not inhibit NGF-induced NOS activity after 6 days (p =
668) (Fig. 3-3C).
Effectveness ofMEK inhibitors, U0126 and PD98059
We wanted to investigate the discrepancy between the PD98059 and U0126
results. Surrisingly, we found that PD98059 only parially blocked neurte extension in
our clone ofPC12 cells (Fig 3-4A and B). In contrast, U0126 was ver effective in
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Figure 3-4. Effect ofMEK inhibitors on neurite extension. Drgs were dissolved in
DMSO. Carer alone controls showed no adverse effects. Cells were preteated with
drg for 30 minutes before addition of 100 ng/ml NGF. Media, drgs and NGF were
replenished ever 48 hours. Cells were scored positive for neurites if they had at least one
neurte two cell diameters long. (A) For the time course five separate fields ofthe same
flask were photographed and scored for neurites. The experiment was performed in
triplicate and data is presented as a mean:: SEM (B) For the dose response five fields
were photographed and scored for neurtes after six days of treatment with either MEK
inhibitor. The experiment is presented as a mean :: SEM.
blocking neurite extension. Afer 6 days ofNGF treatment, 57 %:i 2 % (SEM) ofNGF-
treated cells had neurites. Only 4.3 % :i 1 % (SEM) ofNGF plus 50 11M UOl26-treated
cells while 28 % :i 4 % (SEM) ofNGF plus 50 11M PD98059-treated cells scored positive
for neurtes (Fig. 3-4A). Similarly, increasing doses ofU0126 were much more effective
than PD98059 in blocking neurte extension after six days ofNGF treatment (Fig. 3-4B).
Because PD98059 was only parially effective in blocking neurte extenion and
unable to block nNOS induction, we compared its ability to block Ras- ERK signaling
with that ofU0126. In PC12 cells, ERK becomes phosphorylated within ten minutes of
NGF treatent. (29 58). Since ERK are the physiological substrates ofMEKs, we
were able to address the effcacy of both MEK inibitors with an antibody that recognizes
phosphorylated ERKI and ERK. Fig. 3-5 shows that U0126 is much more effective in
blocking ERK phosphorylation than PD98059. Blots were then reprobed with an anti-
ERK antibody to verfy that the samples contained equal levels ofERK (Fig. 3-5). We
also confied that PD98059 was only parally effective in blocking ERK actvity in a
MA kinase assay (data not shown). We conclude that U0126 is a more effective MEK
inhibitor than PD98059 in our cells, and this explains why U0126 blocks NOS induction
much more effectively than PD98059.
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Figure 3-5. Effect ofMEK inhibitors on ERK phoshorylation.
Cells were pre-incubated with serum free media for one hour
in order to lessen basal levels ofERK phosphorylation and pre-
treated with either 50 jlM U0126, 50jlM PD98059 or carier
alone for 30 minutes. NOF was added for 15 minutes and cellular
extracts were then prepared. Western blots were performed with
an antibodies specific for ERK and phosphorylated ERKs. This
experiment is representative of thee independent results.
Discussion
We have used NGF treated PC12 cells as a model to study the upregulation of
nNOS mRA and protei levels. The Ra-ERK pathway has been extenively studied 
this system and is required for many of the morphological and biochemical changes
induced by NGF (29 58). By two different means we have demonstrated that the Ra-
ERK pathway is required for the induction of nNOS. First, we have shown in wild type
PC12 cells that nNOS is induced at the RNA level as seen using RT PCR and at the
protein level by Wester blotting. In PC12 cells infected with an adenovis that
expresses a dominant negative Ras, nNOS is not induced at either the RNA level or the
protein level (Fig. 3-2A and 3-2B). We have also shown by citrullne assay that a
competent Ras is necessar for the induction of NOS activity (Fig. 3-2C). Although we
did not examne the transcriptional regulation of nNOS , Rife et al. have suggested that
MA kinase might influence expression through trancrption factors associated with the
2 nNOS promoter (146). It is interesting to note that the induction ofnNOS mRA
and NOS activity apparently precedes that of nNOS protein. This fiding may be due to
the relative low sensitivity of the Wester blot analysis as compared with the NOS
activity assay. Second, we dicovered that U0126, but surriingly not PD98059
blocked the induction of nNOS protein and activity (Fig. 3- , and 3-3C). Finally, we
have obsered that the p38 kiase inibitor SB203580 did not block NGF-induced nNOS
(Fig. 3-3B and 3-3C). Since the JN kinase pathway is not activated in NGF-treated
PC12 cells (69), we conclude the Ra-ERK pathway, not the p38 or JN kinase
pathways, is required for nNOS induction.
The different potencies for U0126 and PD98059 were puzling at fist. PD98059
has been used extensively to investigate MA kinase signaling. In paricular, PD98059
has been reported to inibit neurite extenion in PC12 cells (149- 151). Yet in our clone
ofPC12 cells , PD98059 did not block nNOS induction and only parially blocked ERK
phosphorylation and neurite extenion (Fig. 3- , 3- , 3-4 and 3-5). A possible
explanation for this difference is that varous clones ofPC12 cells contain different
numbers of TrkA receptors so that signaling vares from clone to clone. Alteratively,
the potency ofPD98059 as a MA kinase inibitor might var from clone to clone.
Indeed, the developers ofPD98059 noted that this drg did not block neurite extension in
some clones (70). Thus it seems that even the residual activation of MA kinase
signaling as seen in NGF plus PD98059 treated PC12 cells (Fig. 3-5) is suffcient to
induce nNOS (Fig. 3-3A and 3-C). In contrast, the drg U0126 was ver effective in
blocking MEK activity, neurite extension and nNOS induction (Fig. 3- , 3- , 3-4 and
5). Most likely, this is because U0126 is significantly more potent than PD98059 (72).
Moreover, U0126 is equally potent towards MEKI and MEK2 while PD98059 is more
potent towards MEKI (72 152). This is important because both isoform ofMEK are
activated with similar kinetics in NGF-treated PC12 cells (153). In conclusion, U0126 is
a much more effective drg and should be used in future studies ofPC12 cells.
This report provides the fist evidence ofnNOS regulation by the Ras-ERK
pathway. It is already known that the expression of the other two NOS isotyes can be
regulated by MA kinases. Estogen has been shown to induce eNOS in pulmonar
arer endothelial cells through the Ras-ERKpathway (154). Simlarly, fibroblast growth
facor and epideral growth factor stimulate expression of eNOS through Ra-ERK in
ovine fetoplacental arery endothelial cells (155). In addition, all three MA kinase
pathways have been implicated in iNOS regulation. The Ras- ERK pathway has been
associated with cytokie-induced iNOS in cardiac myocytes and microvascular
endothelial cells (121 156). The JN pathway has been reported to be important for
iNOS expression during co stimulation of mouse macrophages with lP-gama and
TN-alpha (157). Likewise, the p38 pathway has been implicated in iNOS induction in
mouse astrocytes, bovine carilage-derived chondrocytes and in an oligodendrocyte cell
line (CG4 cells) (158-160). In addition, p38 may downegulate iNOS in glomerlar
mesangeal cells (161). The p38 pathway can synergie with the Ra-ERK pathway to
regulate iNOS (162-164). Thus consistent with their perasive role in signaling, the
MA kinase pathways paricipate in the expression of all three NOS isotyes.
While it is now clear that the MA kinase pathways regulate the expression of
nitric oxide synthases, it is becomig evident that NO itself or NO-related species are
important regulators of MA kinase signaling. Ras is a target of NO and the site of the
molecular interaction beeen Ra and nitrc oxide has been determned (13 165). It has
been reported that NO-activation ofRas in PC12 cells is important for surval responses
(166). These observations have been extended to primar cortical cultures in rats where
it has been shown that NO controls NMA receptor-induced activation ofRas (167). 
addition to Ras, all three MA kinase pathways also appear to be susceptible to NO-
induced activation (168 169). Hence, it is becomig apparent that nitric oxide can modify
components of the MA kinase pathways. It remins to be determed whether NO
modification of MA kinase pathways creates a feedback loop to modulate signaling
from cell surface receptors and to induce crosstal between the three MA kinase
pathways.
CHATER IV
NITRIC OXIDE DOES NOT ACT THROUGH GUANATE CYCLASE DURG
DIFRENTIATION OF PC12 CELLS
Introducton
We have descrbed a novel signaling pathway during the differentiation ofPC12
cells involving NGF, nitrc oxide, p53 and p21 W AFI (84). It is unclear the mechanism
by which NO acts to induce differentiation and cell cycle arest in this system. One 
the best characterized modes of NO action is through the activation of guylate cyclase
and the production of cGMP (1). Cyclic GMP, in tur can activate cyclic GMP-
dependent protein kinase (PKG) and these signaling molecules can control several
neuronal functions , including neurotranmitter release, ion chanels, and calcium
signaling (170).
A role for cGMP in the differentiation of several different cell types has been
reported. An increase in the intracellular cGMP concentration induced granulocytic
differentiation of the human promyelocytic cell line HL60 (171). Similarly, the
differentiation of rat osteoblast-like cells, huma melanocytes, Seroli cells, and norml
human bone maow cells all involve cyclic GMP (172-175).
In PC12 cells, cGMP has multiple, vared roles. Cyclic-GMP acts in opposition
to tetanus toxin blockade of acetylcholine release (176). Nitric oxide can amlify
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calcium-induced gene transcrption in PC12 cells and this effect is cGMP-dependent
(177). Conversely, NO selectively inhibits voltage-dependent calcium influx in neuronal
cells through a cGMP-dependent mechanism (178). Others have shown NO, through
cGMP, to modulate agonist-evoked intracellular Ca2+ (179 180) which in tur can
activate the ryanodine receptor (181). Stimulation of the cGMP pathway by NO induces
expression ofthe imediate early genes c-fos andjunB in PC12 cells (182). In trophic
factor-deprived PC12 cells, NO can delay death by a cGMP-mediated mechanism (183).
We examied the possibility that NGF-induced differentiation ofPC12 cells
through NO requires the activation of guanylate cyclase. We fid that unlike the
inibition of NOS which inibits differentiation, inibition of guanylate cyclase does not
inhibit differentiation as measured by the induction of the neuronal marker f3-tubulin m.
Moreover, 8Br-cGMP, a cell-pereable analog ofcGMP failed to induce differentiation
ofNGF-treated, NOS-inhibited PC12 cells.
Materials and Methods
Cell Culture
PC12 cells from Dr. David Kaplan (Montreal Neurological Institute) were
maintained in Dulbecco s modified Eagle s medium supplemented with 10% heat-
inactivated horse serum, 5% heat-inactivated fetal bovine serum, and 1 00 g/ml
gentamycin at 37 oC under 5% C02. These cells were found to be mycoplasma-free by
the diect culture method (MYCOTRI, Irve Scientific, Santa Ana, CA). For PC12 cell
differentiation, plastic dishes were treated overnght at 4 oC with 15 g/m1 rat tail
collagen (Sigma) and 15 g/ml poly- lysine(::300 000 Da, Sigma). The dishes were
rined with distiled water, and then PC12 cells were plated in defied medium, as
descrbed (98), and treated wih 100 ng/ml NGF (2.5 S , Bioproducts for Science
Indianapolis). After 3-4 days oftreatment, cells with neurites at least five cell diameters
long were scored as positive.
Drugs
Nitro-L-arginine methyl ester (L-NAM) competes with arginine for binding
to all three isoform of NOS and blocks enzatic activity (9). In these studies , we used
20 mM L-NAM and the same concentration ofthe inactive enantiomer, D-NAM, as a
control. L-NAM used at this concentration is thought to be specific for NOS and with
little effect on PC12 metabolism, growth rates, and NGF induction of immediate-early
genes (83). L Y83583 (Calbiochem) is a competitive inibitor of soluble guanylate
cyclase. 8 Br-cGMP (Sigma) is a soluble analog of cyclic GMP.
Western Blottig
After treatment with NGF and NO drgs, cells were extracted as descrbed (17).
These samples (40 g of protein/lane) were boiled under reducing conditions, subjected
to electrophoresis on a 12.5% polyacrylamide gel, and electrotranfered to an
Immobilon-P membrane (Milipore, Bedford, MA). Residua proteins in the gel were
stained with Coomasie Blue to confIrm even loading of the gel. The membrane was
blocked for 1 h with 10% powdered milk in 0.2% Tween 20, Tris-buffered saline, and
then incubated with monoclonal anti-f3-tubulin isotye m (Sigma) 1: 800 in TTBS for 1 h.
Immunoreactive proteins were detected with horseradish peroxidase-conjugated
seconda antibodies (Amersham, Arlington Heights, IL) and a chemiluminescence
reagent (100).
Results
Previously we have shown that inhibition of NOS durng NGF-induced neuronal
differentiation blocks differentiation as measured by neurte extension or expression of
neuronal markers (84). We tested whether blocking cGMP production with the guanylate
cyclase inhibitor L Y83583 could also block the expression ofNGF-induced
differentiation. NGF induces the neuronal marker tubulin m after three days in defmed
media (Figure 4- 1). LY83583 does not inhbit NGF-induced levels off3-tubulin il
(Figure 4-1) or neuronal differentiation (data not shown). It should be noted that this
concentration ofL Y83583 has been shown to inhibit guanylate cyclase activity in NGF-
treated PC12 cells (184). We attemted to restore differentiation ofNGF-treated, NOS-
inhibited PC12 cells with a soluble analog of cGMP. 8 Br-cGMP was not able to restore
neurite extension in L-NAME-treated PC12 cells (Figue 4-2).
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Figue 4-2. 8 Bromo-cyclic GMP canot rescue L-NAM inhibited differentiation.
Cells were cultued for three days in defined media and either untreated, treated with
NGF (100 ng/ml), treated with L-NAM (20 mM and/or 8Br-cGMP (0. , 1 and 5 mM).
Data is presented as a mean +/- SEM of three independent experments.
Discussion
Our evidence indicates that NO does not act through guanylate cyclase durng the
differentiation ofPC12 cells. Conflicting data exists over the importance of cyclic GMP
durng PC 12 differentiation. One group reprts that nere growth factor increases the
cyclic GMP level and activates the cyclic GMP phosphodiesterase in PC 12 cells (125).
Moreover, another group has reported that NO donors enance neurotrophin-induced
neurte outgrowth through a cGMP-dependent mechanism (185). Conversely, a recent
report shows evidence that NGF decreases soluble guylate cyclase levels in PC12 cells
(186). While the evidence for a role for cyclic GMP is NGF-treated PC12 cells is
conflicting our results along with another group (184) argue against a role for cGMP in
PC12 neuronal differentiation.
It has become increasingly evident that nitric oxide does not act exclusively
through cGMP. Nitric oxide is involved in neuronal process outgrowth and remodeling
in dorsal root ganglion neurons in a cGMP independent manner (187). In PC12 cells
nitric oxide attenuates potassium-stimulated dopame release in a cyclic GMP
independent fashion (188). NO can regulate the activity of caspases independent of
cGMP (24 25). It is now known that nitrosylation of cysteine residues by NO is a major
mechanism for NO action. We next investigated whether NO functions through
nitrosylation to regulate p53 levels. Earlier we demonstrated that NO paricipates in p53
induction during PC12 differentiation (Chapter 2).
CHATER V
NIRIC OXIE INITS HDM2-p53 BINING
THROUGH S-NITROSYLATION OF HDM2
Introduction
The tumor suppressor p53 is an imortant regulatory molecule involved in cell
cycle arest durg development and as a mediator of apoptosis in response to stress (43-
45). Mutation ofp53 is one of the most common genetic lesions in human cancer.
Although p53 is dispensable for norml cell growth and development, cells and mice
lacking functional p53 show a predisposition to cell proliferation, chromosomal
abnormlities, and tumorigenesis, suggesting that p53 plays a crtical role in maintenance
of genome integrty (43). p53 fuctions as a transcrption factor that activates
transcription of genes involved in cell cycle arest (p21 W AFI and cyclin G), DNA
dae (GADD45 ) and apoptosis (Bax) (43). Mdm is another trancriptional target of
p53 and its interactions with p53 are the focus of this study (53 54).
The mdm gene was first detected in a screen for oncogenes present on a mouse
double minute chromosome (49). The human homolog ofthe gene, hdm, has been
shown to be overexpressed in a number of human tuors (189). Hdm can regulate p53
in two ways. Hdm binds p53 and inactivates its trancriptional activity (50). Hdm also
regulates p53 levels by promoting its degradation (51 52). Hdm is an E3 ligase that
ubiquitinates p53 (190). Thus Hdm paricipates in a negative feedback loop that keeps
p53 levels in tight check.
Nitrc oxide is a ubiquitous signaling molecule with diverse and varied functions.
NO has been shown to be a signal that increases p53 levels in physiological and
pathological situations. Durng neuronal differentiation ofPC12 cells NO acts as a
cytostatic agent by inducing p53 (84). Simlarly, in vascular smooth muscle cells NO
activates p21 WAF 1 through p53 (191). Durg apoptosis, NO plays a critical role in p53
induction but the molecular mechanism of this induction is not known (76 192).
One way that nitric oxide exerts its actions in cells is through S-nitrosylation of
cysteine residues. In the case ofRas , S-nitrosylation enhances its activity (13). For most
proteins, though, S-nitosylation is an inactivating modification. Caspase-3 is inactivated
by S-nitrosylation in vivo (25). Several other proteins including receptors, proteases , and
trancrption factors are reprtedly S-nitrosylated (5) (Table 2).
It has recently been shown that Hdm-p53 binding is sensitive to oxidation and
that the sulfhydrl-modifyg agent N-ethylmaleimde destroys the binding capacity of
Hdm to p53 (193). In this study we test whether nitric oxide can effect the ability of
Hdm to bind p53 . We fid that NO reacts with Hdm and thereby inhibits Hdm-p53
binding. Moreover, we demonstrate that this inhibition is reversible, consistent with
nitrosylation of cysteine. Finally, we identify a cysteine residue proximal to the Hdm-
p53 binding domain that is responsible for the NO inhibition of binding.
Materials and Methods
Reagents
Dithiothreitiol, N-ethylmaleimide, cysteine, reduced glutathione and
tetramethylbenzidine (TMB) diydrochloride tablets were all purchased from Sigma.
DETNNO (NOC-18) was purchased from Alexis.
GST-Hdm2
The plasmid GST-Hdm (a. a. 1-188) was a gift from David Lane (194). Bacteria
cultures were grown to OD 0.8. They were cooled to room temperature, induced with 1
mM IPTG and then grown for 4 h at 27 C. Cells were harvested and pellets were flash
frozen in liquid nitrogen. Pellets were resuspended in ice cold buffer A (0. 5 M NaCl, 2.
mM KCl, 10 mM Na HP0 , 1.8 mM KH , ImM PMSF, 1 mM EDT A, 10 mM 2-
mercaptoethanol, pH 7.3) and lysed twice in a French press. After centrifugation the
soluble fraction was incubated with 1 m1 of Glutathione Sepharose 4B beads for Ihour at
room temerature and then overnight at 4 C. The entire mixture was then spun and
washed 6 times with PBS and then the beads were packed in a column. The protein was
then eluted with buffer B (50 mM Tris/HCl, 10 mM reduced glutathione, 0.5 M NaCl, 1
mM EDTA, 1 mM PMSF, 10 mM 2-mercaptoethanol pH 8.0). Fractions containing
GST-Hdm were pooled, aliquotted and stored at -
Preparation of p53 protein in SF9 cells
His-tagged, full-length p53 baculovis was a gift from Steve Jones. Sf9 cells
were infected and cells were harested 48 hours after infection. The cells were extacted
at 4 C with 1% Triton X- I00, 150 mMNaCl, 50 mM Tris/HCl (pH 7. 5) and 1 mM
PMSF for 30 miutes. After centrfugation extract was passed through a 0.45Jlm fiter.
The p53 protein was purified on a His-Bind Quick 900 Cardge (Novagen). Protein
expression and purity were checked by western blotting with a monoclonal anti-6xHis
antibody (Clontech). Purfied p53 was aliquotted and stored at -
ELISA Assay
The Hdm-p53 interaction was assayed by ELISA using a similar assay to one
descrbed previously (194). EIA assay plates (Costar) were coated overight at 4 C wih
IJlg/ml ofp53 in PBS. Plates were blocked with PBST-M (PBS , containing 5% milk
powder and 0. 1% Tween 20) for one hour at room temperature. GST-Hdm (2. Jlg/ml)
in PBS was incubated with NO donor and with or without cysteine or DTT for one-half
hour at room temperature. An equal volume of2X PBST-M was then added to the
sample and then applied to the ELISA plate for one hour at room temerature. After
three washes wells were probed with a polyclonal anti-GST antibody (1: 10 000) from
Sigma in PBST-M and then a HR-linked polyclonal anti-rabbit antibody (1:1 500) from
Amersham in PBST -M. Substrate development was performed with TMB tablets (0.
mg/ml) in 0.05 M phosphate-citrate buffer pH 5.0 containing 0.006% hydrogen peroxide.
After 15 minutes reactions were stopped with an equal volume of 1M phosphoric acid
and read at 450 TI. All washing beteen steps was done with PBS.
Site diected mutagenesis
Site diected mutagenesis and generation ofthe mutant plasmid GST -HdmC77 A
was performed with the QuickChange TM Site-Directed Mutagenesis Kit from Stratagene
following standard protocols. The mutant sequence was confIrmed by automated
sequencmg.
Results
We tested whether treating Hdm with a nitrc oxide donor would affect its
binding to p53. We employed a GST-Hdm fuion protein that includes the fist 188
amno acids ofHdm. This fragent contai the p53-binding domain. In ELISA
assays we confied earlier results that the thiol-modifying agent N-ethylmaleimide
(NM) inibits Hdm2-p53 binding (Figure 5-1). Using the nitrc oxide donor DETNNO
5 and 10 mM we demonstrated that nitric oxide inibits this binding as well (Figue
1). This inibition is blocked by the addition of an excess of reducing agent. When
excess DTT (10 mM is present DETNNO was unable to inhibit binding (Figue 5-2).
Presumably, the excess DTT competes with Hdm for the nitrc oxide. Moreover
addition of excess amounts of cysteine also blocked nitric oxide inhibition ofHdm-p53
binding (Figure 5-3). These results are consistent with nitric oxide effecting binding by
nitrosylating sulfhydrl residues.
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Figure 5-1. DET AlO inhbits Hdm2-p53 bindig. ELISA assays
were performed on p53-coated plates treated with Hdm2 (2.5 g/m1)
alone, Hdm2 + 10 mM NEM or Hdm2 + increasing am ooots of
DETAIO (mM). Data is presented as a mean:: SEM (n=15).
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Figure 5-2. DTT blocks DET A/O inhibition ofHdm2-p53 binding.
ELISA assays were performed on p53-coated plates that were presented
withHdm2 (2.5 g/ml) alone, Hdm2 + 10 mMDTT, Hdm2 + 10 mM
DETA/O or Hdm2 + 10 ro DTT and 10 ro DET A/O. Data is
presented as a mean :: SEM (n = 9).
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Figure 5-3. Cysteine blocks NO inhibition ofHdm2-p53 bindig.
ELISA assays were peronned on p53-coated plates treated with
Hdm2 (2.5 J.g/ml) alone, Hdm2 + 10 mM cysteine, Hdm2 + 10 mM
DETA/O or Hdm2 + 10 mM cysteine and 10 mM DETA/NO. Data
is presented as a mean :: SEM (n = 9).
In order to ensure that the effect of nitric oxide was specific for Hdm we
performed several controls. We coated ELISA plates with GST-Hdm instead ofp53 and
tested whether the presence of nitric oxide effected the binding of the anti-GS T antibody
to GST-Hdm. In these experiments, nitrc oxide had no effect (data not shown). We
also tested whether nitrc oxide was modifyg p53 intead ofHdm2. Plates coated with
p53 were treated with DET NNO and tested for their ability to bind Hdm. In these
experments DETNNO had no effect on Hdm-p53 binding (data not shown). From
these experents we conclude the effect of nitrc oxide on Hdm-p53 binding is due to a
reaction of NO with Hdm2.
We tested whether the effect of nitric oxide was reversible. DETNNO was
reacted with Hdm for one-half hour and then the miure was split in two. Half of the
sample was then incubated with DTT for an additional one-half hour while the other half
of the samle was untreated. The results from these experiments clearly indicate the
inhibition by nitrc oxide to be reversible, again consistent with nitrosylation of a
sulfhydrl group (Fig 5-4).
Previously, it had been shown that the Hdm-p53 reaction was susceptible to
oxidation (194). This fact coupled with our results with NO led us to examne which
cysteine residue is modified by NO and thereby inhibits binding. In our Hdm fragent
there are three cysteine residues; C2 , C77 and C127. C77 seemed to be the most likely
residue to be modified due to its proximity to the Hdm and p53 binding interface
(193 195) (Figure 5-5). In addition we found that this C77 is highly conserved in human
mouse, chicken, frog and zebrafish (Fig 5-5). We mutated C77 to A in Hdm and tested
DETA/O
DTT
Figure 5-4. DETA/O inibition of Hdm-p53 binding is reversible.
ELISA assays were perormed on p53-coated plates. Hdm2 (2.5 JIg/ml)
alone or Hdm2 + 10 mM DETA/O were incubated for one-half hour
then half of each sample was then incubated with 10 mM DTT for
one-h alf hour. Data is presented as a mean :I SEM (n=9).
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Figure 5-5. The N-terminus of Hdm2 contains three cysteines (C2
C77 and C127). C77 is highly conserved and is located within the
p53-binding domain (aa 50- 100). Sequences were aligned using the
Clustal Method in MegAlign.
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the ability of this mutated protein to bind p53 and the effect of nitric oxide on this
binding. The C77 A mutation did not affect norml binding when compared to the wild
tye protein (Fig. 5-6). However, when the mutant protein was treated with DETNNO
there was no inhibition ofHdm-p53 binding (Fig. 5-7). Thus, the C77 to A mutation
renders Hdm insensitive to NO inibition and provides strong evidence that NO exers
its action through this paricular cysteine residue.
Discussion
We have presented a potential mechanism by which NO increases p53 levels.
Nitrc oxide inibits binding ofHdm, a negative regulator ofp53 levels, to p53 (Fig. 5-
1). This inhibition of binding would allow p53 levels to go unchecked and remain high
or increase. This inhibition can be blocked by the reducing agent DTT or the NO
scavenger, cysteine (Fig. 5-2 and 5-3). Importantly, the inhibition of Hdm-p53 binding
is reversible suggesting this may be a relevant form of regulation in vivo (Fig. 5-4).
Additionally, we have identified C77 in our Hdm fragent as the target of NO.
Mutation of this residue to alanine has no effect on norml binding (Fig. 5-6). Nitric
oxide has no effect on HdmC77 A-p53 binding unlike wild-type Hdm-p53 binding,
which is inhibited by nitric oxide (Fig. 5-7).
In this study we focus on the N-ternus ofHdm that contain the p53 binding
domain. However, Hdm regulates p53 by two mechanisms. In addition to its ability to
bind and inactivate p53 , Hdm also regulates p53 stability by targeting the p53 protein
wild type
mutant
pg/ml of Hdm2
Figure 5-6. Wild tye and mutat Hdm2 bind to p53 similarly.
ELISA assays were performed on p53-coated plates using
increased concentrations of wild type and mutant (C77 A) Hdm2.
Hdm2 (wt)
Hdm2 (C77 A)
DETAINO
Figure 5-7. MutantHdm2lacks responsiveness to DETA/O.
ELISA assays were perfonned on p53-coated plates with either
Hdm2 wild type (2.5 J!g/ml) orHdm2 (C77A) (2.5 J!g/ml) with
or without 10 mM DETA/O. Data is represented as a mean ::
SEM (n=9
for proteasomal degradtion (51 52). A recent report suggests that Mdm, the murine
version ofHdm, is RIG figer-dependent ubiquitin protein ligase for itself and p53.
This study identifies several cysteine residues in the Mdm RIG finger that are crtical
for its ability to degrade p53 (190). Thus, it is possible that in full length Hdm2, these
cysteines are additional targets of NO .
The importance ofC77 ofHdm is not imediately apparent as it does not
paricipate diectly in p53 binding. However, the crstal strcture does show that C77 is
proximal to the p53-binding pocket (Figue 5-8 A). Specifically, C771ies in close
proximity to two residues, V75 and P91 , that paricipate in Van der Waal's interactions
with p53 (195 196). C77 is bured in a hydrophobic pocket diectly behind the p53-
interacting residues (P91 , V75, V88 and L82) (Fig. 5-8 B). Reaction of NO with C77
will make this sidechain both larger and more polar. One can propose two possible
models. The nitrosylated C77 sidechain might pop out of the hydrophobic pocket, which
would distort the p53-interaction domain. Alteratively, the nitrosylated sidechain might
remain in the pocket, distorting the layer ofp53-interacting residues , which mae up
much of the hydrophobic pocket. Furher structural studies would be required to resolve
this question.
Is Hdm nitrosylation a physiologically relevant form of p53 regulation?
Previously, we have shown that NO induces p53 accumulation durg neuronal
differentiation (84). We also know that NO acts in a cGMP independent manner during
PC12 differentiation (184) and (Chapter IV. NO is also known to induce p53 durg
apoptosis. Activation of iNOS in RAW 246.7 macrophages results in p53 accumulation.
Figure 5-8 A. Cys77 (yellow) is in close proximity to other Hdm2
residues (gray) that bind p53 (green). The crystal structure (194)
was used with the MIDAS display system (195) to create ths model.
Figure 5- 8 B. Cys77 is located in a hydrophobic pocket.
Moreover, work with NO donors showed a clear increase in p53 levels while NO removal
blocked p53 induction (76 111 112 197). Despite the clear lin between NO and p53
induction durig apoptosis the molecular mechanism is not understood. In both cases
neuronal differentiation and apoptosis, NO might increase p53 levels by inactivating
Hdm.
CHATER VI
ADDITIONAL DISCUSSION
Taken in their entirety, the results from this thesis describe the importance of a
signal tranduction pathway activated by NGF that involves nitric oxide, p53 and W AFI
which leads to cell cycle arest and ultimately neuronal differentiation in PC12 cells
(Chapter 11. In addition, it is now known that NGF induces NOS through activation of
the Ras-ERK MA kinase pathway (Chapter Il). Moreover, nitric oxide exers its
acions in a cyclic GMP-independent maer in this system (Chapter IV). Finally, we
present in vitro evidence that nitric oxide could regulate p53 levels by blocking the p53
regulator, Hdm, from binding to p53 (Chapter V).
When presented in total these data suggest an appealing pathway important for the
control of neuronal differentiation (Figue 6-1). However, several caveats must be
considered. One key aspect to consider was the culture conditions used to differentiate
PC12 cells. In Chapters IT and IV we used defied media to quicken the speed of
differentiation. In Chapter m, however, ser-contaiing media was used to optime
the assays used for NOS detection. It is important to note that the timng of NOS , p53
and p21 W AFI induction is different beeen the two culture conditions. Another group
has looked carefully at the NGF-induction ofp53 and p21WAFl in serm and serum-ITee
media (129). The induction of NOS as viewed by diaphorase staining in serm-free
conditions (three days) or by R T - PCR, western blotting and citrulline assay (from two to
NGF
TrkA
Ras-ERK
nNOS Induction
Hdm2
p53 Levels Increase
p21WAFl
Cell Cycle Arrest
Neuronal Differentiation
Figue 6- 1. A signal transduction pathway important for the control of neuronal
differentiation.
six days) in serm-containing conditions are consistent with the timing of the induction
oftotal p53 levels seen by us (Chapter II and others (129).
A significant amount of the data in this thesis relies on the specificity of varous
chemical inhibitors. Recently, a study has been published investigating the specificity
and limitation of some ofthese drgs (198). The three kinase inibitors used in this
thesis, PD98059, U0126 and SB203580, are all extremely specific for their substrates.
Nonetheless, in the case ofPD98059 and U0126 we found varg results due to their
different potencies (Chapter m). An effect on neurte extension but not NOS induction
was seen by SB203580 (Chapter m). While the guylate cyclase inibitor L Y83583 did
not have an effect on the induction of a differentiation maker (Chapter IV), it was used
at a concentration that has been used by others to block guanylate cyclase activity in
PC 12 cells (184). The use of chemcal inibitors has been a ver important tool in
biochemical research. However, an over-reliance on these drgs can lead to faulty
conclusions. When available, other means should be used to bolster results obtained with
chemical inhibitors. The use of a dominant negative expressing protein, as we did in
Chapter m, is one convenient alerative to a chemcal inibitor. Finally, if no effct i
seen with a chemical inhibitor, the ideal control is to assay the activity of the pro
substrate of the drg.
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